Profiel
Richard Chesworth worked as Senior Vice President-Research at Epizyme, Inc. and as Chief Scientific Officer at Kymera Therapeutics, Inc. He holds a doctorate degree from the University of Oxford and an undergraduate degree from Imperial College London.
Eerdere bekende functies van Richard Chesworth
| Bedrijven | Functie | Einde |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 22-10-2021 |
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Richard Chesworth
| University of Oxford | Doctorate Degree |
| Imperial College London | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
